Chronic inflammation in comorbidities is thought to be the main cause of the low multiorgan dysfunction (MODS) threshold and death. The failure of the immune system's homeostatic feedback loop triggers ongoing inflammatory activation. Beginning with obesity as a pathological beginning of noncommunicable disease (NCD) and deficiency of adiponectin. Which has anti-inflammatory properties, inhibits the secretion and activation of various inflammatory cytokines (TNF-, IL-1, IL-6, and IFN-) and maintains innate immunity. This is an analytic observational study with a cross-sectional design. The sampling technique is total sampling. The study was conducted in the COVID-19 isolation room at RSUD Dr. Soetomo Surabaya from May to June 2021. Blood samples were taken on day 0 of treatment, with autoanamnesis data and medical records. The normality test uses the Kolmogorv-Smirnov, and Contingency coefficient test was conducted to assess the correlation between nominal type variables. There were 153 research subjects; MODS was experienced by 82.35% of subjects, and mortality was experienced by 32.68%. There was a relationship between MODS and mortality (P = 0.016). The median ADP level in the study was 2.8 ng/mL and was associated with multiorgan failure (P = 0.047) and mortality (P = 0.019). With a cut-off value of 3.15 g/mL, the ROC ADP area under the curve (AUC) is 0.378 (P = 0.048, CI 0.265-0.491).Length of stay (LoS) and degree of ARDS were significantly related to ADP levels (P = 0.007 and P = 0.004). Initial ADP levels were associated with mortality and MODS. ADP levels are related to LoS and the degree of ARDS, or the initial P/F ratio value.

COVID-19

adiponectin

mortality

comorbidity

MODs

COVID-19